Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Sanofi
  6. News
  7. Summary
    SAN   FR0000120578


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Sanofi: Availability of the Q3 2021 Memorandum for modelling purposes

09/24/2021 | 01:30am EDT

Availability of the Q3 2021 Memorandum for modelling purposes

Paris, France September 24, 2021 - Sanofi announced today that its Q3 2021 Memorandum for modelling purposes is available on the "Investors" page of the company's website:

As for each quarter, Sanofi prepared this document to assist in the financial modelling of the Group's quarterly results. This document includes a reminder on various non-comparable items and exclusivity losses as well as the foreign currency impact and share count. Sanofi's third-quarter 2021 results will be published on October 28, 2021.

About Sanofi

Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

Media Relations Contacts
Sandrine Guendoul
Tel.: +33 (0)6 25 09 14 25

Media Relations main line:
Tel.: +33 (0)1 53 77 46 46

Investor Relations Contacts
Investor Relations team:
Tel.: +33 (0)1 53 77 45 45

Sanofi Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi’s ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that COVID-19 will have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. Any material effect of COVID-19 on any of the foregoing could also adversely impact us. This situation is changing rapidly and additional impacts may arise of which we are not currently aware and may exacerbate other previously identified risks. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2020. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.




  • 21_09_24_Memorandum

Primary Logo

Source: Sanofi

2021 GlobeNewswire, Inc., source Press Releases

All news about SANOFI
10/15SANOFI : New long-term data reinforcing promising safety and efficacy profile of brain-pen..
10/14SANOFI : Goldman Sachs keeps its Buy rating
10/14SANOFI : JP Morgan keeps its Buy rating
10/13SANOFI : Update from Sanofi regarding Kevzara (sarilumab) - Supply constraints anticipated..
10/13SANOFI : Says Multiple Sclerosis Drug Well-Tolerated at One-Year Mark of Phase 2b Extensio..
10/13SANOFI : Multiple Sclerosis Drug Remains Tolerable After One Year In Extension Study
10/13SANOFI : New long-term data reinforcing promising safety and efficacy profile of brain-pen..
10/13SANOFI : Expects Rheumatoid Arthritis Drug Supply To Remain Constrained Until 2022
10/13NHTHERAGUIX : NH TherAguix reporte son projet d'introduction en bourse sur le marché Euron..
10/12SANOFI : Warns of Kevzara Supply Constraints Until Early 2022
More news
Analyst Recommendations on SANOFI
More recommendations
Sales 2021 37 371 M 43 523 M 43 523 M
Net income 2021 6 025 M 7 016 M 7 016 M
Net Debt 2021 9 268 M 10 793 M 10 793 M
P/E ratio 2021 17,2x
Yield 2021 3,99%
Capitalization 104 B 120 B 121 B
EV / Sales 2021 3,02x
EV / Sales 2022 2,75x
Nbr of Employees 99 412
Free-Float 88,4%
Duration : Period :
Sanofi Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 82,66 €
Average target price 104,90 €
Spread / Average Target 26,9%
EPS Revisions
Managers and Directors
Paul Hudson Chief Executive Officer & Director
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
Serge Weinberg Chairman
John C. Reed EVP & Global Head-Research & Development
Nestle Frank Global Head-Immunology Therapeutic Research Area
Sector and Competitors
1st jan.Capi. (M$)
SANOFI5.03%120 395
JOHNSON & JOHNSON1.74%421 513
ROCHE HOLDING AG17.78%342 644
NOVO NORDISK A/S56.38%238 110
PFIZER, INC.12.71%231 668